에임드바이오

0009K0KOSDAQ자연과학 및 공학 연구개발업

52.8 / 100

Reference Date: 2026-06-10

Financial Score17.5 / 40

News Sentiment18.3 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 41.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

AimedBio is a global biotech company specializing in the development of antibody-drug conjugate (ADC)-based anticancer therapeutics, leveraging patient-derived models and proprietary linker-payload technology. As a spin-off from Samsung Seoul Hospital, the company has achieved milestones through technology transfers and co-development agreements with global pharmaceutical firms since 2024.

Number of Employees

52people

Average Salary

69.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

238.89Industry Average 62.700.0Point

3.8x industry avg (risky)

PBR

8.66Industry Average 3.240.0Point

2.7x industry avg (risky)

ROE

5.12Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

0.37Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 6.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

3.0 / 4

Detailed News Sentiment

13 totalPositive 9Neutral 3Negative 1Average Sentiment Score 73.1

Positive
바이오헤이븐, BHV1530 임상 1상 순항...에임드바이오 웃는다
에임드바이오의 기술이전 프로젝트가 임상 1상 성공적 진행으로 긍정적 영향을 받고 있다.
Positive
[서울데이터랩] 코스닥 2.33% 올라 1049.96…외국인·기관 순매...
코스닥 상승으로 에임드바이오 포함 코스닥 상장사들의 주가가 전반적으로 상승 추세를 보임.
Neutral
삼성, 2000억 규모 삼성 라이프사이언스 펀드 3호 조성
삼성 라이프사이언스 펀드 조성 소식은 관련 기업들에 대한 간접적인 긍정적 영향을 미칠 수 있으나, 에임드바이오(0009K0)에 직접적인 영향은 제한적입니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 25,800Won52-week high 72,50052-week low 25,800

1-month return0.0Point

1m -41.63% (strong drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주주명부폐쇄기간또는기준일설정2026-06-05
Neutral주주총회소집결의 (임시주주총회)2026-06-05
Neutral투자판단관련주요경영사항(임상시험계획승인신청)2026-05-27
Neutral분기보고서 (2026.03)2026-05-15
Neutral[기재정정]분기보고서 (2026.03)2026-05-15